MedTrace Logo

HDR Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer

NCT03424694 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 199

Last updated 2022-03-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate High-dose rate (HDR) brachytherapy (1 vs 2 fractions on single implant) as monotherapy for the treatment of low risk and intermediate risk prostate cancer

Conditions

Interventions

RADIATION

HDR brachytherapy as monotherapy

Sponsors & Collaborators

  • CR-CSSS Champlain-Charles-Le Moyne

    lead OTHER

Principal Investigators

  • Marjory Jolicoeur, MD · CSSS Champlain-Charles-Le Moyne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-22
Primary Completion
2019-06-22
Completion
2022-02-22

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03424694 on ClinicalTrials.gov